Table 2 Comparison of indications and use of the three hexavalent vaccines (from Orsi et al., 2018 [7], modified)
Infanrix Hexa® [11] | Hexyon® [12] | Vaxelis® [13] | |
|---|---|---|---|
Hib PRP | 10 μ g conjugated to tetanus toxoid | 12 μ g conjugated to tetanus toxoid | 3 μ g conjugated to membrane protein meningococcus (OMP) |
Pertussis PT | PT 25 μ g FHA 25 μ g PRN 8 μ g | PT 25 μg FHA 25 μg | Pertussis PT 25 μ g FHA 25 μ g PRN 8 μ g PT 25 μ g FHA 25 μ g PT 20 μ g FHA 20 μg PRN3 μg FIM type 2.3: 5 μg |
Diphtheric toxoid | Not less than 30 IU * average value | Not less than 20 IU * lower limit 95% CI | Not less than 20 IU * lower limit 95% CI |
Tetanus toxoid | Not less than 40 IU | Not less than 40 IU | Not less than 40 IU |
IPV polio | Inactivated virus Types 1, 2, 3 | Inactivated virus Types 1, 2, 3 | Inactivated virus Types 1, 2, 3 |
Hepatitis B HBsAg produced in | Saccharomyces cerevisiae | Hansenula polymorpha | Saccharomyces cerevisiae |
Ready to use No Yes Yes | No | Yes | Yes |
Co-administration with other vaccines included in the national schedule | Yes | Yes | Yes |
Minimum age | Yes | Yes | Yes |
Minimum age | Not specified | 6 weeks | 6 weeks |
Antibody persistence studies | Yes | Yes | Yes |
Effectiveness data | Yes | Yes | Not available |